Efter aflæggelse af Q2 regnskabet afholdt Novo Nordisk ledelse med analytikerne deres investorpræsentation, som kan ses via dette link. Her har man mulighed for at høre Q&A med analytikerne efter ledelsens indledende præsentation.
Novo Nordisk indleder præsentationen sådan:
Strategic Aspirations 2025 | Highlights first six months of 2021
Adding value to society:
• Initiated Diabetes Compass with the WDF to improve
access to diabetes care in low- and middle-income
countries
• Reaching 15 countries in Changing Diabetes in
Children by including Ghana
Progress towards zero environmental impact:
• 45% reduction in CO2 emissions vs the first six months
of 2019 and ~15% reduction in supplier CO2 emissions
Evolve culture and ensure distinct core capabilities:
• Launch of gender diversity target
Diabetes care:
• Ozempic® approved in China
• Resubmission of semaglutide 2.0 mg in the US
Obesity care:
• Decision to initiate phase 3a development with 50 mg oral
semaglutide in obesity
• Approval of Wegovy™, semaglutide 2.4 mg, in the US
Other serious chronic disease:
• Phase 3a development programmes initiated for treatment
of NASH and Alzheimer’s Disease
• Stem cell R&D licence agreement with Heartseed and
acquisition of Prothena’s ATTR amyloidosis programme
